DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective of 86 German Patient Groups" report has been added to ResearchAndMarkets.com's offering.
German patient groups have traditionally been suspicious of pharma ...
The relationship between patient groups in Germany and the pharma industry is, in one way at least, more complex than in other countries. Because German people pay a significant proportion of their income towards their healthcare, German citizens-and the patient groups representing them-inevitably suspect for-profit healthcare companies of wishing to exploit the German model of funding national healthcare by charging ever higher prices for their products.
Evidence for such suspicion and distrust is readily seen in the fact that fewer patient groups in Germany maintain working partnerships with pharma than do patient groups from almost any other country.
39% of 2017's respondent German patient groups stated that the pharma industry as a whole had an Excellent or Good reputation-the highest percentage ever attained from German patient groups [see chart 3]. The equivalent figure in 2017 among patient groups worldwide, though, was higher, at 43%.
Key Topics Covered:
- Executive Summary
- Patient-Group Relationships With Pharma, 2017
- Industry-Wide Findings, 2017
- Rankings Of The 19 Pharma Companies, 2017 V. 2016 Among German Patient Groups Familiar With The Companies
- Positioning Of Six Pharma Companies, 2017 V. 2016 Among German Patient Groups That Work/Partner With The Companies
- Profiles Of The 19 Companies, 2017
Companies Mentioned
- Abbvie
- Amgen
- Astrazeneca
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Grnenthal
- Gsk
- Janssen
- Merck & Co
- Merck Kgaa
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Takeda
For more information about this report visit https://www.researchandmarkets.com/research/q9s58x/corporate?w=4
